Provided herein are heterocyclic compounds and pharmaceutical formulations that can be used to treat bacterial infections. Also provided herein are methods of making and using the heterocyclic compounds and pharmaceutical formulations.

The novel bisphosphonic acid ester derivatives represented by the following formula (1):
YCy(NH).sub.m(CH.sub.2).sub.nC(X)(PO(OR.sup.1)(OR.sup.2)).sub.2(1)
wherein each symbol is as defined in the DESCRIPTION, which has an amino group substituted by a heterocyclic group or a heterocyclic group containing a nitrogen atom, and the acid moiety is esterified with a POM group, an n-butanoyloxymethyl (BuOM) group and the like, exhibit a superior direct or indirect cytotoxicity effect on tumor cells and virus infected cells.

The novel bisphosphonic acid ester derivatives represented by the following formula (1):
YCy(NH).sub.m(CH.sub.2).sub.nC(X)(PO(OR.sup.1)(OR.sup.2)).sub.2(1)
wherein each symbol is as defined in the DESCRIPTION, which has an amino group substituted by a heterocyclic group or a heterocyclic group containing a nitrogen atom, and the acid moiety is esterified with a POM group, an n-butanoyloxymethyl (BuOM) group and the like, exhibit a superior direct or indirect cytotoxicity effect on tumor cells and virus infected cells.

The present invention includes a molecule, a method of identifying said molecule, and a method of using said molecule to inhibit the interaction of A and Drp1 proteins. The molecules including diethyl (3,4-dihydroxyphenethylamine)(quino-lin-4-yl)methylphosphonate (DDQ); [10-(4,5-dimethoxy2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenylphosphonium methanesulfonate (MitoQ); 3-Hydroxynaphthalene-2-carboxylic acid (3,4-dihydroxy-benzylidene)-hydrazide (Dynasore); and/or 3-(2,4Dichloro-5-methoxyphenyl)-2,3-dihydro-2-thioxo-4(1H)-quinazolinone/3-(2,4-Dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone (Mdivi-1).

Provided are: a rare earth complex which has a novel structure, which exhibits compatibility with organic solvents and resins, and which exhibits excellent luminescent properties as a luminescent element; and a use thereof. This rare earth complex includes: a phosphine oxide compound represented by general formula (1); at least one rare earth ion selected from the group consisting of Ce, Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, and Lu; and a ligand compound. In the rare earth complex, the coordination numbers of the ligand compound and the phosphine oxide compound represented by general formula (1) to the rare earth ion are 8-10, and a plurality of the phosphine oxide compounds represented by general formula (1) and a plurality of the rare earth ions are provided with a crosslinked structure. ##STR00001##

Provided are: a rare earth complex which has a novel structure, which exhibits compatibility with organic solvents and resins, and which exhibits excellent luminescent properties as a luminescent element; and a use thereof. This rare earth complex includes: a phosphine oxide compound represented by general formula (1); at least one rare earth ion selected from the group consisting of Ce, Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, and Lu; and a ligand compound. In the rare earth complex, the coordination numbers of the ligand compound and the phosphine oxide compound represented by general formula (1) to the rare earth ion are 8-10, and a plurality of the phosphine oxide compounds represented by general formula (1) and a plurality of the rare earth ions are provided with a crosslinked structure. ##STR00001##

The present disclosure provides heterocycle compounds with RIP2 kinase inhibitory activity, pharmaceutical compositions comprising the same, methods using the same and applications thereof. The present disclosure provides compounds of Formula (I), as inhibitors of RIP2 kinase. These compounds can be used for preventing and/or treating RIP2 kinase-related diseases and/or conditions.

##STR00001##

The present invention relates to a tyrosine kinase inhibitor and a pharmaceutical composition comprising same. The tyrosine kinase inhibitor of the present invention has the structures as shown in the following formula (I) or (II):

##STR00001##

The present invention relates to a tyrosine kinase inhibitor and a pharmaceutical composition comprising same. The tyrosine kinase inhibitor of the present invention has the structures as shown in the following formula (I) or (II):

##STR00001##

An organic electron transport material, which includes a phosphine oxide derivative represented by the following Formula (1):

##STR00001##

R.sup.1 represents an atomic group which has one or more of either or both of aryl and heteroaryl groups and may have one or more phosphine oxide groups, R.sup.2 to R.sup.11 each independently represent an atom or an atomic group selected from the group consisting of a hydrogen atom, a halogen atom, a cyano group, a nitro group, a carboxyl group, a formyl group, a carbonyl group, an alkoxycarbonyl group, and a trifluoromethyl group.